Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

14.22
-0.9500-6.26%
Pre-market: 14.320.1000+0.70%08:32 EDT
Volume:3.32M
Turnover:47.40M
Market Cap:1.96B
PE:-3.94
High:15.01
Open:14.91
Low:14.00
Close:15.17
52wk High:15.87
52wk Low:4.82
Shares:138.00M
Float Shares:107.00M
Volume Ratio:1.06
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6118
EPS(LYR):-3.0800
ROE:-319.07%
ROA:-29.08%
PB:23.21
PE(LYR):-4.62

Loading ...

H.C. Wainwright Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)

TIPRANKS
·
Apr 21

BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO

Reuters
·
Apr 20

Compass Pathways Price Target Maintained With a $14.00/Share by BTIG

Dow Jones
·
Apr 20

Psychedelic Drug Stocks Surge with Compass Pathways up 37%; Atai Beckley up 28%. Trump Accelerates Psychedelic Research With $50 Million Ibogaine Commitment

Benzinga Earnings
·
Apr 20

Definium Therapeutics Adds 15.3%, Compass Pathways Rises 40%, GH Research Gains 16.4%

THOMSON REUTERS
·
Apr 20

Enveric Biosciences up 150%, U.S.‑Listed Shares of Cybin Rise 2.7%

THOMSON REUTERS
·
Apr 20

BUZZ-U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen

Reuters
·
Apr 20

Top Premarket Gainers

MT Newswires Live
·
Apr 20

Psychedelic Pharmaceutical Companies' Shares Rise Following Executive Order

Dow Jones
·
Apr 20

Psychedelic Drug Developers Rise Premarket After Trump Orders FDA to Expedite Reviews

THOMSON REUTERS
·
Apr 20

Definium Therapeutics up 14.5%, Compass Pathways up 21.5%, GH Research up 18.9%, Enveric Biosciences up 6.6%, U.S.‑Listed Shares of Cybin up 15.5%

THOMSON REUTERS
·
Apr 20

Compass Pathways CEO joins Needham Virtual Psychedelics Forum panel

Reuters
·
Apr 20

BUZZ-Psychedelic drug developers rise after Trump signals regulatory support

Reuters
·
Apr 20

Compass Pathways commends White House order to speed psychedelic treatment access

Reuters
·
Apr 19

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

THOMSON REUTERS
·
Apr 19

Compass Pathways Plc - Already Working With FDA on Rolling Submission for Comp360 in Treatment-Resistant Depression

THOMSON REUTERS
·
Apr 19

BUZZ-Psychedelic drug developers rise after CBS report Trump backs more research

Reuters
·
Apr 17

Compass Pathways publishes 2025 annual report

Reuters
·
Apr 16

Compass Pathways announces annual shareholder meeting

Reuters
·
Apr 16

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere

Reuters
·
Apr 14